Results 1 to 10 of about 198,185 (239)

Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model [PDF]

Frontiers in Immunology
ObjectivesThe present study aimed to assess the therapeutic efficacy of neutralizing monoclonal antibodies targeting a prominent proinflammatory cytokine in a PBMC transfer-induced humanized mouse model of systemic inflammation.MethodsInflammatory ...
Liang Zhang, Liang Zhang, Jacqueline Wax, Jacqueline Wax, Torsten Goldmann, Torsten Goldmann, Afsaneh Mehrpouyan, Afsaneh Mehrpouyan, Antje Müller, Frank Petersen, Frank Petersen, Gabriela Riemekasten, Xinhua Yu, Xinhua Yu   +13 more
doaj   +2 more sources

Aptamers Targeting IL17A and Its Receptor Suppress IL17 Signaling in Different Cell Types [PDF]

Pharmaceuticals
Background/Objectives: Interleukin-17A (IL-17A) is a key pathogenic cytokine in autoimmune arthropathies. Current monoclonal antibody inhibitors targeting the IL-17/IL-17RA axis demonstrate clinical efficacy but face significant limitations, including ...
Anastasiya Solovieva, Dariya Rippinen, Anna Davydova, Veronika Goncharova, Vladimir Koval, Mariya Vorobyeva, Maksim Korolev   +6 more
doaj   +2 more sources

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study

Научно-практическая ревматология, 2021
Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of the AURORA phase II study.Objective: to evaluate the efficacy safety and immunogenicity of LVL in methotrexate (MTX)
V. I. Mazurov, E. G. Zotkin, I. Z. Gaydukova, E. P. Ilivanova, T. V. Kropotina, T. V. Plaksina, O. B. Nesmeyanova, N. F. Soroka, E. A. Kunder, E. A. Dokukina, Yu. N. Linkova, N. A. Kravtsova, P. S. Pukhtinskaya, A. V. Eremeeva, A. V. Zinkina-Orikhan, A. A. Lutckii   +15 more
doaj   +1 more source

Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)

Современная ревматология, 2021
Levilimab is anti-interleukin-6 receptor (IL6R) monoclonal antibody. The article presents data obtained during 24 weeks of the SOLAR phase III study.Objective: to confirm efficacy and safety of levilimab in combination with methotrexate (MTX) in patients
V. I. Mazurov, M. A. Korolev, A. M. Prystrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Kretchikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, Yu. N. Linkova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, A. V. Eremeeva, A. A. Lutckii   +25 more
doaj   +1 more source

Biological sex is associated with heterogeneous responses to IL-6 receptor inhibitor treatment in COVID-19—A retrospective cohort study

Scientific Reports, 2023
COVID-19 is associated with higher inflammatory markers, illness severity and mortality in males compared to females. Differences in immune responses to COVID-19 may underpin sex- specific outcome differences.
Dan F. Stein, Conor Foley, Matt Byott, Eleni Nastouli, Gareth Ambler, Nishkantha Arulkumaran   +5 more
doaj   +1 more source

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR

Научно-практическая ревматология, 2023
Background. Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo.
V. I. Mazurov, A. M. Lila, M. A. Korolev, A. M. Prystrom, A. V. Kundzer, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Krechikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, Yu. N. Linkova, A. V. Eremeeva, A. A. Lutckii, E. L. Nasonov   +27 more
doaj   +1 more source

Takayasu’s Arteritis Diagnosed in an Adolescent Patient with Crohn’s Disease: Management of Biologicals

Life, 2021
We report a 14-year-old man with Crohn’s disease (CD) who developed right upper arm pain while being treated with the anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, infliximab.
Kazuya Kishimoto, Yuji Nozaki, Toshiharu Sakurai, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura   +5 more
doaj   +1 more source

Two Biosensors for the Determination of Interleukin-6 in Blood Plasma by Array SPRi

Biosensors, 2022
Interleukin-6 (IL-6) is a biomarker of inflammation, the advanced stage of COVID-19, and several cancers, including ovarian cancer. Two biosensors for the determination of IL-6 in blood plasma by array SPRi have been developed.
Beata Szymanska, Zenon Lukaszewski, Lukasz Oldak, Beata Zelazowska-Rutkowska, Kinga Hermanowicz-Szamatowicz, Ewa Gorodkiewicz   +5 more
doaj   +1 more source

The immunobiology of humanized Anti-IL6 receptor antibody: From basic research to breakthrough medicine

Journal of Translational Autoimmunity, 2020
The clinical use of monoclonal antibodies is well established in human medicine and has been amongst the most important contributions of basic science to clinical disease.
Yoshiyuki Ohsugi
doaj   +1 more source

IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19

Journal of Innate Immunity, 2022
Acute respiratory distress syndrome (ARDS) in COVID-19 has been associated with catastrophic inflammation. We present measurements in humans and a new animal model implicating a role in danger-associated molecular patterns.
Georgios Renieris, Eleni Karakike, Theologia Gkavogianni, Dionysia-Eirini Droggiti, Emmanouil Stylianakis, Theano Andriopoulou, Victoria-Marina Spanou, Dionyssios Kafousopoulos, Mihai G. Netea, Jesper Eugen-Olsen, John Simard, Evangelos J. Giamarellos-Bourboulis   +11 more
doaj   +1 more source